Envestnet Asset Management Inc. raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 14.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 214,006 shares of the company’s stock after buying an additional 26,352 shares during the period. Envestnet Asset Management Inc.’s holdings in Eli Lilly and were worth $18,000,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in LLY. First Command Financial Services Inc. increased its position in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the period. Heritage Trust Co acquired a new position in Eli Lilly and during the first quarter valued at approximately $135,000. Penserra Capital Management LLC increased its position in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares during the period. Crestwood Advisors Group LLC acquired a new position in Eli Lilly and during the first quarter valued at approximately $179,000. Finally, Alpha Windward LLC increased its position in Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock valued at $189,000 after buying an additional 44 shares during the period. Institutional investors and hedge funds own 75.47% of the company’s stock.
Eli Lilly and Company (NYSE LLY) opened at 84.75 on Friday. Eli Lilly and Company has a 12-month low of $64.18 and a 12-month high of $86.72. The stock has a 50 day moving average of $82.29 and a 200-day moving average of $81.07. The company has a market cap of $89.52 billion, a PE ratio of 40.98 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.96 by $0.02. Eli Lilly and had a return on equity of 26.64% and a net margin of 10.13%. The company had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.22 billion. During the same quarter in the previous year, the firm earned $0.83 earnings per share. Eli Lilly and’s revenue was up 7.5% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and Company will post $4.12 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.45%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is 100.48%.
COPYRIGHT VIOLATION WARNING: This report was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://stocknewstimes.com/2017/07/21/envestnet-asset-management-inc-increases-position-in-eli-lilly-and-company-nyselly.html.
Several equities analysts recently commented on the stock. BidaskClub upgraded shares of Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Barclays PLC upped their price target on shares of Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Tuesday, July 4th. Jefferies Group LLC restated a “buy” rating and issued a $96.00 price target (up from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Citigroup Inc. upped their price target on shares of Eli Lilly and from $92.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, April 19th. Finally, Morgan Stanley downgraded shares of Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price target on the stock. in a research note on Monday, April 17th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $87.75.
In other news, insider Melissa S. Barnes sold 1,900 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the transaction, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Enrique A. Conterno sold 25,000 shares of the business’s stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $82.76, for a total value of $2,069,000.00. Following the transaction, the senior vice president now directly owns 114,217 shares of the company’s stock, valued at approximately $9,452,598.92. The disclosure for this sale can be found here. Insiders have sold 474,733 shares of company stock valued at $39,634,487 in the last three months. 0.20% of the stock is owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
